We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

U.S. Corporate Wellness Market 2025 BURLINGAME, CA, UNITED STATES, March 17, 2025 /EINPresswire / -- The Global U.S. Corporate W ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.62, expectations were $-0.7. Operator: Greetings, and welcome to the Relmada ...

NDV-01 forms a spherical soft matrix within the bladder that sequesters ... in patients who have failed other therapies, including BCG immunotherapy, and expansion into other NMIBC subtypes ...

Previously, the immunotherapy, Bacillus Calmette-Guerin, BCG, was the cornerstone of treatment ... NDV-01 forms a spherical soft matrix within the bladder that sequester drugs and releases ...

In the boardroom, excitement dominates—75% of executives rank AI as a top strategic priority, according to BCG’s AI Radar report ... The Human-AI Collaboration Matrix reminds us that while ...

Previously, the immunotherapy Bacillus calmetarin BCG causes the cornerstone of treatment ... NVA1 forms a spherical soft matrix within the bladder that sequester drugs and releases it is in ...